(Rac)-WAY-161503 (3-30 mg/kg; intraperitoneal injection; male C57BL/6J mice) treatment dose-dependently decreases locomotor activity, an effect that is blocked by the 5-HT2C/2B antagonist SER-082. Additionally, the decreased locomotor activity produced by 10 mg/kg DOI is potentiated in the 5-HT2A KO mice.
Animal Model: |
Male C57BL/6J mice with hallucinogen 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) |
Dosage: |
3 mg/kg, 10 mg/kg, 30 mg/kg |
Administration: |
Intraperitoneal injection |
Result: |
Dose-dependently decreased locomotor activity, an effect that was blocked by the 5-HT2C/2B antagonist SER-082.
|